Liao Rongrong, Lin Yuexia, Zhu Lihui
Institute of Animal Science and Veterinary Medicine, Shanghai Academy of Agricultural Sciences, 2901 Beidi Road, Shanghai, China.
Mol Biol Rep. 2018 Dec;45(6):2913-2923. doi: 10.1007/s11033-018-4358-6. Epub 2018 Sep 7.
Multidrug resistance (MDR) is still a major reason for therapeutic failure in cancers. The mechanisms underlying MDR are multifactorial and are not fully understood. miRNAs are evolutionarily conserved non-coding RNAs that function as key post-transcriptional regulators of gene expression. Emerging evidence indicates a vital role of miRNAs in the resistance to cancer treatments and suggests their potential for cancer therapy, as they can modulate multiple mechanisms link to the development of MDR. This review summarizes the recent findings on the role of miRNAs in MDR, and highlights the molecular targets and mechanisms of miRNA regulated pathways in MDR. Finally, the challenges and prospects of miRNA-targeted therapies for reversing drug resistance are reviewed.
多药耐药性(MDR)仍然是癌症治疗失败的主要原因。MDR的潜在机制是多因素的,尚未完全了解。微小RNA(miRNA)是进化上保守的非编码RNA,作为基因表达的关键转录后调节因子发挥作用。新出现的证据表明miRNA在癌症治疗耐药性中起着至关重要的作用,并暗示了它们在癌症治疗中的潜力,因为它们可以调节与MDR发展相关的多种机制。本综述总结了关于miRNA在MDR中作用的最新发现,并强调了miRNA调节的MDR途径的分子靶点和机制。最后,综述了针对miRNA的逆转耐药性治疗的挑战和前景。